Skip to main content
. Author manuscript; available in PMC: 2020 Aug 24.
Published in final edited form as: Brain Pathol. 2019 Jan;29(1):75–84. doi: 10.1111/bpa.12673

Table 1.

The clinicopathologic features for 14 cases of anaplastic myxopapillary ependymoma. Cases are ordered by age of presentation (eight pediatric cases followed by six adult cases). More than one size or location is listed for cases with recurrences, separated by commas. The term “initial” is used to indicate the initial resection, a first recurrence is denoted as 1st, a second recurrence is denoted as 2nd. Features considered anaplastic are highlighted in green. Yellow boxes indicate the presence of necrosis that occurred after radiation or chemotherapy, and therefore was not considered an anaplastic feature; this is also indicated by an asterisk. Involvement of the adjacent tissue was assessed by histologic and/or radiographic findings. In cases with a large tumor size and direct invasion of the adjacent bone or soft tissue (case #12 and #10), the integrity of the tumor capsule would be lost. In cases with bone erosion, bone remodeling, involvement of sacral rootlets, involvement of dura or an entrapped ganglion, this was not taken as a direct indication of capsule integrity. M: male, F: female, MVP: microvascular proliferation, HPF: high power fields, STR: subtotal resection, GTR: gross total resection, Res: resection in which gross total or subtotal resection was not specified, XRT: radiation therapy, pXRT: partial course of radiation therapy, Chem: chemotherapy, C: cervical, T: thoracic, L: lumbar

Case # 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Age at MPE diagnosis in years, (age at anaplasia diagnosis, if later) 6 7 10 10 11 12 13 16, (20) 31, (32) 31, (45) 40 45, (57) 50 55
Gender F F M M M M M F M F F M M F
Location L4-S1 (intradural) T12-L3 (intradural) S1-S2 (intradural) L1-L2 (intradural, centered at conus medullaris) filum terminale (L4–5, S2–3) and S1 nerve root (3 masses) (intradural) lumbar mass, lumbar and sacral (intradural) L1-L2 with multiple smaller lesions (posterior fossa, C, T, and L cistern) (intradural) L3-L4 & L5-S1, multiple T and L lesions (intradural) sacral filum terminale region mass with smaller T lesions (intradural) sciatic notch, pelvic & sciatic masses (unclear if MPE was a primary soft tissue form) floor of 4th ventricle T11-L2, L1, T8-L5 (originally an intradural mass filling the thecal sac) L5-S3 (intradural) L1-L2, L2 (intradural)
Size size not specified not specified 4.2 cm 4.5 cm 3 cm mass on imaging 3.2 cm, 1.5 and 1 cm main mass 3.8 cm 1.7 and 1.0 cm, multiple (up to 1.6 cm) not specified initial size not known, 10 cm and 5.5 cm 5 cm 11.5 cm, 10 cm, size of second recurrence not specified 8.5 cm 2.7 cm, 2.3 cm
Ki-67 LI (data source) 20% (initial resection) 11% (initial resection) 34% (initial resection) 15% (initial resection) 14% (initial resection) 10%, 17% (initial resection, 1st recurrence) 8% (initial resection) 10% (1st recurrence) 10% (9m re-resection) 40% (1st recurrence) 20% (initial resection) 26% (1st recurrence) 10% (initial resection) 20% (initial resection)
Mitotic Index per 10 HPF 12 10 20 6 5 3, 2 6 6 7 7 5 17 14 7
Necrosis Yes No Yes: focal non-palisading No Yes: non-palisading Yes: palisading (only on recurrence) No No * Yes: non-palisading and palisading * Yes: non-palisading and palisading Yes: focal non-palisading * Yes: non-palisading Yes: non-palisading and palisading Yes: non-palisading
MVP Yes Yes Yes Yes: small foci of MVP Yes: multiple foci Yes (initial and recurrence) Yes No Yes Yes Yes Yes: prominent Yes: extensive Yes
Onset of anaplastic features initial resection initial resection initial resection initial resection initial resection initial resection initial resection recurrence present on recurrence/second surgery at 9 months first recurrence initial resection first recurrence initial resection initial resection
Treatment GTR, proton therapy STR, XRT GTR, proton therapy GTR, XRT GTR Initial: GTR 1st: GTR, XRT STR, XRT Initial: GTR 1st: Res, XRT Initial: STR, Chem, pXRT 1st: STR Initial: Res, XRT 1st (pelvic mass): GTR (sciatic mass): GTR, Chem STR, proton therapy Initial: STR, XRT 1st: GTR 2nd: GTR, XRT GTR, XRT Initial: GTR, XRT 1st: unspecified
Recurrence/Metastasis status none reported within 2 yrs stable residual disease ~1.5 yrs none reported within 1 yr none reproted within 4 months none reported within 1 month 1st: 1 yr, nothing additional reported over the following 6 yrs stable residual disease at 4 yrs recurrence at 4 years lost to clinical follow-up after 2 years, patient died at age 36, no autopsy 1st: 14 yrs Lung metastasis: 14 yrs patient died at age 48 none reported within 2.5 yrs 1st: 12 yrs 2nd: 15 yrs patient died 16 yrs after diagnosis, age 60 with extensive local disease none reported within 9 yrs 1st: 18 months, no subsequent clinical follow-up available
Documented recurrence after anaplasia N/A N/A N/A N/A N/A recurred once after anaplasia N/A N/A N/A one additional surgery after anaplasia was diagnosed, both masses were present at 14 yrs, surgeries were separated by 4 months N/A recurred once after anaplasia N/A recurred once after anaplasia
Involvement of adjacent tissue by histologic and/or radiographic findings No No Yes: sacral bone erosion but not invasion, entrapped ganglion No No Microscopic dural invasion, no signifigant involvement of adjacent tissues No No No Yes: invasion of adjacent soft tissues No first recurrence destroyed L1 vertebrae, extended into paraspinal tissues, just prior to death imaging showed a large soft tissue mass invading L2-L4 veterbral bodies, extending into paraspianal and left psoas muscles Yes: involvement of sacral rootlets and dura, with sacral bone remodeling (cortical thinning and destruction without invasion) No
CSF dissemination No No No No No Yes Yes Yes Yes Yes: found 14 yrs after initial No Y: at time of recurrences suspected drop metastasis Yes